Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Medications for Multiple Sclerosis and Risk of Malignancy: What Next?

Neurotherapeutics(2021)10.1007/s13311-021-01107-5Source: DataRank Database

Medications for Multiple Sclerosis and Risk of Malignancy: What Next? is a research paper published in Neurotherapeutics (2021). On theSindex it has a DataRank of 0. It has been cited 7 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access7 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 0.49)OA: bronzeTopics (40)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (2)

Anthony T. Reder ORCID,Daniel B. Horton ORCID

Live enrichment

PubMed:34409568 PMC:PMC8608937 OpenAlex:https://openalex.org/W3194747306

National Institute of Arthritis and Musculoskeletal and Skin Diseases

Grant: K23AR070286

National Institutes of Health

Grant: 5K23AR070286-03

Drugs, Germs, and Joints: Antibiotics, Gut Microbiota, and Juvenile Idiopathic Arthritis

FWCI

0.49

Citation Percentile

0.7%

Influential Citations

Citation Trend

2022

2023

2024

2025

2026

bronzeLicense: Elsevier Non-Commercial

journalhttps://link.springer.com/content/pdf/10.1007/s13311-021-01107-5.pdf

BRONZEhttps://link.springer.com/content/pdf/10.1007/s13311-021-01107-5.pdf

publisherhttps://link.springer.com/content/pdf/10.1007/s13311-021-01107-5.pdf

publisherhttps://link.springer.com/article/10.1007/s13311-021-01107-5/fulltext.html

publisherhttps://api.elsevier.com/content/article/PII:S1878747923007614?httpAccept=text/xml

Fields of Study

Cytokine Signaling Pathways and InteractionsPI3K/AKT/mTOR signaling in cancerLung Cancer Treatments and MutationsMedicine0301 basic medicine0303 health sciences03 medical and health sciencesHumansImmunosuppressive AgentsMultiple SclerosisNeoplasmsRisk Factors

MeSH Terms

HumansImmunosuppressive AgentsMultiple SclerosisNeoplasmsRisk Factors

Keywords

Multiple sclerosisMedicineMalignancyDiseaseContext (archaeology)Autoimmune diseasePopulationNeurologyHarmIntensive care medicineImmunologyDermatologyInternal medicinePsychiatryPsychologyCancerAdverse effectsCommentaryPharmacovigilanceRisk FactorsNeoplasmsHumansImmunosuppressive Agents

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being